Rethinking the pharma R&D lifecycle with AI in mind
Drug Discovery World
AUGUST 7, 2024
The inequality between near-zero-cost AI-driven drug discovery and skyrocketing costs for clinical trials and regulatory approval will create a bottleneck, stalling promising drugs from reaching patients unless AI is equally applied across the entire R&D lifecycle. Singhal is the company’s president; Wickramasekara its CEO.
173 
Let's personalize your content